BioAtla (NASDAQ:BCAB) Cut to Neutral at HC Wainwright

HC Wainwright downgraded shares of BioAtla (NASDAQ:BCAB) from a buy rating to a neutral rating in a research report report published on Wednesday morning, Marketbeat.com reports. HC Wainwright also issued estimates for BioAtla’s Q4 2024 earnings at ($0.33) EPS, FY2024 earnings at ($1.46) EPS, Q1 2025 earnings at ($0.33) EPS, Q2 2025 earnings at ($0.34) EPS, Q3 2025 earnings at ($0.34) EPS, Q4 2025 earnings at ($0.39) EPS, FY2025 earnings at ($1.40) EPS, FY2026 earnings at ($1.74) EPS, FY2027 earnings at ($1.29) EPS and FY2028 earnings at ($0.99) EPS.

Separately, JMP Securities reissued a “market outperform” rating and issued a $5.00 target price on shares of BioAtla in a report on Monday, September 16th.

BioAtla Stock Performance

BCAB opened at $1.56 on Wednesday. The company’s 50-day simple moving average is $1.91 and its two-hundred day simple moving average is $1.87. BioAtla has a 52-week low of $1.14 and a 52-week high of $4.02. The stock has a market capitalization of $75.40 million, a P/E ratio of -0.92 and a beta of 1.03.

BioAtla (NASDAQ:BCAB) last issued its quarterly earnings results on Thursday, November 7th. The company reported ($0.22) earnings per share for the quarter, topping the consensus estimate of ($0.34) by $0.12. The business had revenue of $11.00 million for the quarter. During the same quarter in the previous year, the company earned ($0.70) EPS. Research analysts forecast that BioAtla will post -1.52 EPS for the current fiscal year.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. XTX Topco Ltd grew its position in shares of BioAtla by 7.2% during the third quarter. XTX Topco Ltd now owns 154,967 shares of the company’s stock valued at $273,000 after purchasing an additional 10,384 shares in the last quarter. Massachusetts Financial Services Co. MA grew its holdings in BioAtla by 5.2% during the 3rd quarter. Massachusetts Financial Services Co. MA now owns 569,332 shares of the company’s stock valued at $1,002,000 after buying an additional 28,133 shares in the last quarter. GSA Capital Partners LLP bought a new stake in BioAtla in the 3rd quarter worth approximately $623,000. Chicago Partners Investment Group LLC purchased a new stake in shares of BioAtla during the 3rd quarter worth approximately $44,000. Finally, Vontobel Holding Ltd. bought a new position in shares of BioAtla during the 3rd quarter valued at approximately $28,000. 77.23% of the stock is owned by hedge funds and other institutional investors.

About BioAtla

BioAtla, Inc, a clinical-stage biopharmaceutical company, develops specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. The company's lead clinical stage product candidates include mecbotamab vedotin (BA3011), a conditionally active biologic (CAB) antibody-drug conjugate (ADC), which is in Phase II clinical trial for treating undifferentiated pleomorphic sarcoma and non-small cell lung cancer (NSCLC); and ozuriftabmab vedotin (BA3021), a CAB ADC that is in Phase II clinical trial for the treatment of melanoma and squamous cell cancer of the head and neck.